Finoriq research workspace
Akebia Therapeutics, Inc. (AKBA) Historical Metrics
Review reported fundamentals, derived ratios, valuation context, and historical charts for Akebia Therapeutics, Inc. (AKBA).
Company Snapshot
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Company
- Akebia Therapeutics, Inc. (AKBA)
- Ticker
- AKBA
- Market Cap
- $342M
- Latest Price
- $1.275
- Industry
- Biotech & Pharma
Akebia Therapeutics, Inc. (AKBA) Current Valuation Metrics
Static valuation preview for Akebia Therapeutics, Inc. (AKBA). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 1.64x | Revenue | TTM Q1 2026 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 6.33x | Operating Cash Flow | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -5.4% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 15.8% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 14.0x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.